Is India's Covid testing facing price gaps and delay in data?
India is seeing an uptick in Covid-19 infections, reaching over 7,000 cases. But in contrast to earlier waves, there seems to be gaps in diagnosis and testing.Given the current season of rampant viral infections and many individuals showing symptoms, RT-PCR tests are neither being prescribed widely nor being voluntarily taken."Most of the Covid-19 testing we're seeing today is happening within hospitals, where viral panel testing is mandatory before procedures or in cases of severe symptoms. Neither clinicians nor patients are approaching it with the same urgency anymore," said Dr. Vibhu Kawatra, a Delhi-based pulmonologist and allergy specialist.advertisement
RT-PCR (Reverse Transcription–Polymerase Chain Reaction), which remains the gold standard for detecting Covid-19, works by identifying the virus's genetic material in nasal or throat samples.However, Dr. Kawatra pointed out, "Only a doctor can prescribe an RT-PCR test, and unless the symptoms are severe or hospitalisation is required, the test is often skipped."Even when testing is sought, accessibility and affordability are serious barriers.
RT-PCR (Reverse Transcription–Polymerase Chain Reaction), which remains the gold standard for detecting Covid-19, works by identifying the virus's genetic material in nasal or throat samples. (Photo: AFP)
In the private sector, RT-PCR test prices vary drastically depending on the diagnostic lab. Dr. Path Labs charges upwards of Rs 5,000 for a home collection, while Max Healthcare offers the same at Rs 500. At Dr. Dangs Lab, a home visit costs Rs 700. Similar price ranges are being seen across neighbourhood clinics as well.advertisementThis wide pricing disparity reflects the fragmented nature of the diagnostic sector, proving to be unregulated.But despite this inconsistent pricing model, there seems to be reduced testing rates, coupled with the closure of many free government testing centres.A recent visit to Lok Nayak Hospital in New Delhi revealed that the Covid testing window had been shut down. Many other government-run facilities have scaled back or completely discontinued RT-PCR testing, further limiting testing options for the general public.Rising cases highlight the need for routine testing to monitor its spread."The patients who have died not just had Covid-19 but also had underlying health conditions. It is not always the virus alone, but the comorbidities that tip the scale," said Dr. Sudeep Khanna, gastroenterologist and liver specialist at Indraprastha Apollo Hospitals.DELAY IN VIRUS GENOMIC DATASurveillance at the national level is also facing delays.The Indian SARS-CoV-2 Genomics Consortium (INSACOG), the official body monitoring Covid-19 variants in India, has been slow in releasing updated epidemiological data.
There seems to be reduced testing rates, coupled with the closure of many free government testing centres. ()
Only limited information has been shared so far for newer variants like LF.1, NB.1.8.1, and XFG, making it difficult to gauge the evolving nature of the virus.Public health experts stress the need for proactive surveillance, affordable and accessible testing, and better data transparency.VACCINES STOCKPILEGovernment sources told India Today that there are enough Covid-19 vaccines in storage and ready to use. "We are fully prepared for any situation. We have enough stockpile to meet the requirements of our citizens. Moreover, if needed, we can even supply vaccines to other countries," the sources said.Nearly 1 billion people in India have taken at least one dose of either Covishield or Covaxin.
Only limited information has been shared so far for newer variants like LF.1, NB.1.8.1, and XFG, making it difficult to gauge the evolving nature of the virus. ()
Covishield, manufactured and distributed by the Serum Institute of India under a licence from AstraZeneca, stopped being produced in December 2021 because fewer people were taking it.advertisementSimilarly, Covaxin, India's first home-grown Covid-19 vaccine made by Bharat Biotech with ICMR-NIV, also stopped production in early 2022.Despite the halt in manufacturing, officials say that vaccine availability is not a concern.Doctors believe the current rise in cases may be due to seasonal changes in respiratory infections though global health experts say the protection from past infections and vaccines may be wearing off, which could be causing new spikes in some areas.While general information about Covid-19 continues to be available, there seems to be hindrances in the timely response to the infection.Tune InMust Watch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
36 minutes ago
- The Hindu
US restores some medical research grants, says top Trump official
- A senior US health official on 10 June 2025 admitted President Donald Trump's administration had gone too far in slashing biomedical research grants worth billions of dollars, and said efforts were underway to restore some of the funding. Jay Bhattacharya, director of the National Institutes of Health (NIH), made the remarks during a Senate committee hearing examining both recent cuts to his agency and deeper reductions proposed by the White House in next year's budget. Bhattachartya said he had created an appeals process for scientists and laboratories whose research was impacted, and that the NIH had already "reversed many" of the cuts. "I didn't take this job to terminate grants," said the physician and health economist who left a professorship at Stanford University to join the Trump administration. "I took this job to make sure that we do the research that advances the health needs of the American people." The hearing came a day after more than 60 NIH employees sent an open letter to Bhattacharya condemning policies they said undermined the agency's mission and the health of Americans. They dubbed it the "Bethesda Declaration" -- a nod both to the NIH's suburban Washington headquarters and to Bhattacharya's role as a prominent signatory of the 2020 "Great Barrington Declaration," which opposed Covid lockdowns. Since Trump's January 20 inauguration, the NIH has terminated 2,100 research grants totaling around $9.5 billion and $2.6 billion in contracts, according to an independent database called Grant Watch. Affected projects include studies on gender, the health effects of global warming, Alzheimer's disease, and cancer. Trump has launched a sweeping overhaul of the US scientific establishment early in his second term -- cutting billions in funding, attacking universities, and overseeing mass layoffs of scientists across federal agencies.
Hans India
an hour ago
- Hans India
India Records Over 7,000 Active COVID-19 Cases As Fresh Wave Continues In 2025
India's COVID-19 situation shows continued escalation as active cases reached 7,154 on Thursday morning, according to official data from the Ministry of Health and Family Welfare. The country recorded three additional COVID-related fatalities since Thursday, with two deaths in Maharashtra and one in Madhya Pradesh, bringing the total death count for 2025 to 77. Despite the rising infections, there has been encouraging progress in recoveries, with over 8,000 individuals successfully recovering from the infection throughout the current year. Kerala maintains its position as the most affected state in the current wave, reporting 2,223 active cases on Thursday morning. The southern state continues to account for the largest share of India's COVID-19 burden in 2025. Other states experiencing significant case loads include Gujarat, West Bengal, Delhi, and Maharashtra, according to the Centre's COVID-19 monitoring dashboard. While most states have registered slight increases in active cases, the distribution remains uneven across different regions of the country. Health experts attribute the recent surge to emerging Omicron sub-variants, specifically JN.1, NB.1.8.1, LF.7, and XFC strains. These variants demonstrate enhanced transmissibility compared to previous iterations but generally present with milder symptoms in infected individuals. The World Health Organization currently categorizes these strains as "Variants Under Monitoring," indicating they require careful observation but do not yet warrant classification as variants of concern. This designation reflects a cautious approach while acknowledging their increased spread potential. Medical authorities note that SARS-CoV-2, the virus responsible for COVID-19, has evolved from an unpredictable emergency threat to a more predictable endemic pathogen. The virus now follows recurring seasonal patterns similar to influenza, representing a significant shift in how health systems approach COVID-19 management. This transition suggests that while the virus remains present and active, its behavior has become more predictable, allowing for better preparation and response strategies. Healthcare systems are adapting their protocols to manage COVID-19 as part of routine respiratory illness surveillance rather than emergency pandemic response. The current data reflects ongoing vigilance by health authorities as they monitor transmission patterns and adapt public health measures accordingly.
The Hindu
2 hours ago
- The Hindu
Novavax's COVID-flu combo vaccine shows strong immune response in trial
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against the viruses in a late-stage trial. Both the vaccine candidates were well tolerated with no new safety concerns, the biotech said on 11 June 2025. . Its shares rose 1.3% to $7.29 in premarket trading. The study, which involved about 2,000 participants, tested the safety and immune response of the COVID-influenza combination and standalone flu vaccines compared to its COVID-19 shot Nuvaxovid and Sanofi's flu shot Fluzone HD, respectively. Novavax said the study was not designed to show statistically significant results. The data will be used to design a future late-stage study, which can be submitted for regulatory approval, it said. The Maryland-based biotech, which is shifting its focus to commercialising its candidates through partnerships, said it continues to look for partners that can advance further development of these experimental vaccines. It had signed a licensing deal with Sanofi worth up to $1.2 billion last year to commercialize and further develop its COVID-19 vaccine, Nuvaxovid. Nuvaxovid gained the U.S. approval last month after the Food and Drug Administration missed an April 1 target to approve the shot. The approval, however, limited its use to older adults and at-risk individuals over the age of 12. The traditional protein-based shot offers an alternative to its messenger RNA-based rivals from Pfizer/BioNTech and Moderna. Earlier this week, health secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, fired all members of a U.S. Centers for Disease Control and Prevention panel of vaccine experts — a move public health experts said could undermine confidence in currently available shots.
